Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study of AJM300 in Patients With Active Ulcerative Colitis

Trial Profile

Phase III Study of AJM300 in Patients With Active Ulcerative Colitis

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carotegrast (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Sponsors EA Pharma; Kissei Pharmaceutical
  • Most Recent Events

    • 05 Jul 2019 Planned End Date changed from 1 Mar 2023 to 1 Dec 2020.
    • 08 Mar 2019 Planned End Date changed from 1 Dec 2020 to 1 Mar 2023.
    • 30 Jul 2018 Planned End Date changed from 1 Mar 2023 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top